MUC21 induces the viability and migration of glioblastoma via the STAT3/AKT pathway

Wang,Leibo; Zhang,Xuebin; Liu,Jun; Liu,Qingjun

doi:10.3892/etm.2022.11260

MUC21 induces the viability and migration of glioblastoma via the STAT3/AKT pathway

Authors:
- Leibo Wang
- Xuebin Zhang
- Jun Liu
- Qingjun Liu
View Affiliations

Affiliations: Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin 300350, P.R. China, Department of Pathology, Tianjin Huanhu Hospital, Tianjin 300350, P.R. China
Published online on: March 16, 2022 https://doi.org/10.3892/etm.2022.11260
Article Number: 331
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma (GBM) is a malignant tumor with one of the fastest increasing morbidity and mortality rates. As such, more therapeutic targets need to be developed to combat this disease. Mucin 21 (MUC21) is a human counterpart of mouse epiglycanin and mediates multiple cellular functions. However, its possible effects on GBM and its possible mechanism remain unclear. The current study aimed to clarify the role or MUC21 in the progression of GBM by performing a series of in vitro assays, including Cell Counting Kit‑8, colony formation, wound closure, transwell, and in vivo assays. In the present study, the aberrantly high expression of MUC21 in human GBM tissues and cell lines was observed and it was revealed that it was associated with the clinicopathological feature, tumor recurrence, in patients with GBM. MUC21 promoted the viability and motility of GBM cells in vitro and stimulated tumor growth in vivo. It was further confirmed that MUC21 promoted the progression of GBM via the STAT3/AKT pathway and it was considered that MUC21 could serve as a promising target for the treatment of GBM.

View Figures

View References

1	Park JE, Kim HS, Lee J, Cheong EN, Shin I, Ahn SS and Shim WH: Deep-learned time-signal intensity pattern analysis using an autoencoder captures magnetic resonance perfusion heterogeneity for brain tumor differentiation. Sci Rep. 10(21485)2020.PubMed/NCBI View Article : Google Scholar
2	Dai S, Yan Y, Xu Z, Zeng S, Qian L, Huo L, Li X, Sun L and Gong Z: SCD1 confers temozolomide resistance to human glioma cells via the Akt/GSK3β/β-catenin signaling axis. Front Pharmacol. 8(960)2018.PubMed/NCBI View Article : Google Scholar
3	Kig C, Beullens M, Beke L, Van Eynde A, Linders JT, Brehmer D and Bollen M: Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells. J Biol Chem. 288:24200–24212. 2013.PubMed/NCBI View Article : Google Scholar
4	Mahasenan KV and Li C: Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: A maternal embryonic leucine zipper kinase example. J Chem Inf Model. 52:1345–1355. 2012.PubMed/NCBI View Article : Google Scholar
5	Zhao Y, Zhao Z, Cui Y, Chen X, Chen C, Xie C, Qin B and Yang Y: Redox-responsive glycosylated combretastatin A-4 derivative as novel tubulin polymerization inhibitor for glioma and drug delivery. Drug Develop Res. 82:1063–1072. 2021.PubMed/NCBI View Article : Google Scholar
6	Yoshimoto T, Matsubara D, Soda M, Ueno T, Amano Y, Kihara A, Sakatani T, Nakano T, Shibano T, Endo S, et al: Mucin 21 is a key molecule involved in the incohesive growth pattern in lung adenocarcinoma. Cancer Sci. 110:3006–3011. 2019.PubMed/NCBI View Article : Google Scholar
7	Yi Y, Kamata-Sakurai M, Denda-Nagai K, Itoh T, Okada K, Ishii-Schrade K, Iguchi A, Sugiura D and Irimura T: Mucin 21/epiglycanin modulates cell adhesion. J Biol Chem. 285:21233–21240. 2010.PubMed/NCBI View Article : Google Scholar
8	Tian Y, Denda-Nagai K, Kamata-Sakurai M, Nakamori S, Tsukui T, Itoh Y, Okada K, Yi Y and Irimura T: Mucin 21 in esophageal squamous epithelia and carcinomas: Analysis with glycoform-specific monoclonal antibodies. Glycobiology. 22:1218–1226. 2012.PubMed/NCBI View Article : Google Scholar
9	Kai Y, Amatya VJ, Kushitani K, Kambara T, Suzuki R, Tsutani Y, Miyata Y, Okada M and Takeshima Y: Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma. Histopathology. 74:545–554. 2019.PubMed/NCBI View Article : Google Scholar
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
11	Guo P, Yu Y, Li H, Zhang D, Gong A, Li S, Liu W, Cheng L, Qiu Y, Yao W, et al: TGF-â1-induced miR-503 controls cell growth and apoptosis by targeting PDCD4 in glioblastoma cells. Sci Rep. 7(11569)2017.PubMed/NCBI View Article : Google Scholar
12	Ganguly R, Hong CS, Smith LG, Kornblum HI and Nakano I: Maternal embryonic leucine zipper kinase: Key kinase for stem cell phenotype in glioma and other cancers. Mol Cancer Ther. 13:1393–1398. 2014.PubMed/NCBI View Article : Google Scholar
13	Chen T, Chen Z, Lian X, Wu W, Chu L, Zhang S and Wang L: MUC 15 Promotes osteosarcoma cell proliferation, migration and invasion through livin, MMP-2/MMP-9 and Wnt/β-catenin signal pathway. J Cancer. 12:467–473. 2021.PubMed/NCBI View Article : Google Scholar
14	Ratan C, Cicily K D D, Nair B and Nath LR: MUC Glycoproteins: Potential biomarkers and molecular targets for cancer therapy. Curr Cancer Drug Targets. 21:132–152. 2021.PubMed/NCBI View Article : Google Scholar
15	Matsumura M, Okudela K, Nakashima Y, Mitsui H, Denda-Nagai K, Suzuki T, Arai H, Umeda S, Tateishi Y, Koike C, et al: Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas-implications for the progression of EGFR-mutated lung adenocarcinomas. PLoS One. 14(e0215237)2019.PubMed/NCBI View Article : Google Scholar
16	Cao H, Ye D, Zhao Q, Luo J, Zhang S and Kong J: A novel aptasensor based on MUC-1 conjugated CNSs for ultrasensitive detection of tumor cells. Analyst. 139:4917–4923. 2014.PubMed/NCBI View Article : Google Scholar
17	Zhang L, Strouthos CG, Wang Z and Deisboeck TS: Simulating brain tumor heterogeneity with a multiscale agent-based model: Linking molecular signatures, phenotypes and expansion rate. Math Comput Model. 49:307–319. 2009.PubMed/NCBI View Article : Google Scholar
18	Itoh Y, Kamata-Sakurai M, Denda-Nagai K, Nagai S, Tsuiji M, Ishii-Schrade K, Okada K, Goto A, Fukayama M and Irimura T: Identification and expression of human epiglycanin/MUC21: A novel transmembrane mucin. Glycobiology. 18:74–83. 2008.PubMed/NCBI View Article : Google Scholar
19	Zhang Z, Sun C, Li C, Jiao X, Griffin BB, Dongol S, Wu H, Zhang C, Cao W, Dong R, et al: Upregulated MELK leads to doxorubicin chemoresistance and M2 macrophage polarization via the miR-34a/JAK2/STAT3 pathway in uterine leiomyosarcoma. Front Oncol. 10(453)2020.PubMed/NCBI View Article : Google Scholar
20	Zhang M, Liu Q, Mi S, Liang X, Zhang Z, Su X, Liu J, Chen Y, Wang M, Zhang Y, et al: Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J Immunol. 186:4716–4724. 2011.PubMed/NCBI View Article : Google Scholar
21	Lv X, Wang L and Zhu T: MiR-20a-5p suppressed TGF-β1-triggered apoptosis of human bronchial epithelial BEAS-2B cells by targeting STAT3. Mol Cell Probes. 50(101499)2020.PubMed/NCBI View Article : Google Scholar
22	Shang J, Li Y, Yin G, Li Z, Jiang L and Bai Q: Phosphatidylinositol 3,4,5-trisphosphate-dependent rac exchanger 2 protein facilitates glioma progression via Akt and Stat3 signaling. J Mol Neurosci. 71:1674–1682. 2021.PubMed/NCBI View Article : Google Scholar
23	Kim HI, Lee SJ, Choi YJ, Kim MJ, Kim TY and Ko SG: Quercetin induces apoptosis in glioblastoma cells by suppressing Axl/IL-6/STAT3 signaling pathway. Am J Chin Med. 49:767–784. 2021.PubMed/NCBI View Article : Google Scholar